Protein / target
Growth hormone receptor
Protein at a glance
Biological role
Protein tyrosine kinase activator
Strongest disease association
Laron Syndrome
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Receptor for pituitary gland growth hormone (GH1) involved in regulating postnatal body growth.
View complete UniProt function annotationHide complete annotation
Receptor for pituitary gland growth hormone (GH1) involved in regulating postnatal body growth (PubMed:1549776, PubMed:2825030, PubMed:8943276). On ligand binding, couples to the JAK2/STAT5 pathway (PubMed:1549776, PubMed:15690087, PubMed:2825030, PubMed:8943276)
Subcellular location
Domains and Gene Ontology detail (48)Hide
Domains & features
Gene Ontology
- Ccell surface
- Ccytosol
- Cexternal side of plasma membrane
- Cextracellular region
- Cextracellular space
- Cgrowth hormone receptor complex
- Cmembrane
- Cneuronal cell body
- Cplasma membrane
- Creceptor complex
- Fcytokine binding
- Fgrowth factor binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Growth-factor signalling
- ·growth factor binding
- ·insulin-like growth factor receptor signaling pathway
Cell proliferation & survival
- ·positive regulation of cell population proliferation
Immune signalling
- ·cytokine binding
- ·cytokine-mediated signaling pathway
- ·response to interleukin-1
Metabolic enzyme activity
- ·hormone metabolic process
- ·taurine metabolic process
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
6 medicines meet Open Targets' target-level approved-medicine definition; the 5 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Growth hormone receptor agonist
Indicated for Cachexia, Dwarfism, Pituitary, HIV Infections, Renal Insufficiency, Chronic
Growth hormone receptor agonist
Indicated for Dwarfism, Pituitary
Growth hormone receptor agonist
Indicated for Dwarfism, Pituitary
Growth hormone receptor antagonist
Indicated for Acromegaly
Growth hormone receptor agonist
Indicated for Dwarfism, Pituitary
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene GHR
Gene-level evidence surfaced through the gene GHRthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
6 compounds recorded · 6 approved
View all recorded compounds (6)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
Other modalities — Strong
View underlying tractability evidence (9)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 4 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- New publicationComplex relationship between growth hormone and sleep in children: insights, discrepancies, and implications.
- New publicationRecent insights into the role of hormones during development and their functional regulation.
- New publicationA Superlong-Acting Growth Hormone-Polypeptide Fusion for Growth Hormone Deficiency Treatment.
- New publicationProlactin and Growth Hormone Signaling and Interlink Focused on the Mammosomatotroph Paradigm: A Comprehensive Review of the Literature.
- New publicationGrowth Hormone Action in Somatostatin Neurons Regulates Anxiety and Fear Memory.
- New publicationCancer in growth hormone excess and growth hormone deficit.
- New publicationAging under endocrine hormone regulation.
- New publicationSafety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results.
- Regulatory approval
Approval: Ngenla (EMA)
- Regulatory approval
Approval: Skytrofa (previously Lonapegsomatropin Ascendis Pharma) (EMA)
- Regulatory approval
Approval: Sogroya (EMA)
- Regulatory approval
Approval: NutropinAq (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.
Related literature
Papers indexed under “Receptors, Somatotropin” — a subject heading that covers this protein without being specific to it. Shown as context; not counted as this protein's own research activity.
Europe PMC literature, reached through a MeSH descriptor linked to this protein.